Canada’s Drug Agency | Drugs, Health Technologies and Systems.

lurbinectedin

Details

Generic Name:
lurbinectedin
Project Status:
Pending
Therapeutic Area:
Metastatic small cell lung cancer
Manufacturer:
Jazz Pharmaceuticals Canada Incorporated
Call for patient/clinician input open:
Brand Name:
Zepzelca
Project Line:
Reimbursement Review
Project Number:
PC0431-000
Call for patient/clinician input closed:
Tumour Type:
Lung
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the second-line treatment of adult patients with Stage III or metastatic SCLC who have progressed on or after a platinum-containing therapy.
Submission Type:
Resubmission
Fee Schedule:
Pending
Indications:
Zepzelca, indicated for the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : August 5, 2025